Effects of Atorvastatin on Blood Pressure and Urinary Albumin Excretion

A

Aristotle University Of Thessaloniki

Status

Completed

Conditions

Hypertension
Hypercholesterolemia

Treatments

Drug: Atorvastatin
Drug: Placebo

Study type

Interventional

Funder types

Other

Identifiers

NCT01126684
STAY

Details and patient eligibility

About

To evaluate the possible effects of atorvastatin on ambulatory blood pressure, urinary albumin excretion, insulin resistance and arterial stiffness in hypertensive patients, beyond those on lipid profile. Glycemic parameters, "novel" cardiovascular risk factors and safety parameters will be also evaluated.

Enrollment

50 patients

Sex

All

Ages

18 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • LDL-C>130 or >160 mg/dL (depending on the total risk according to the most recent recommendations25).
  • no previous hypolipidemic medication
  • ability to provide Informed Consent.

Exclusion criteria

  • pregnancy or lactation
  • myocardial infarction or unstable angina within the past 6 months
  • heart failure NYHA class III-IV
  • renal disease (SCr>3 mg/dL or proteinuria>3g/d)
  • liver disease
  • history of malignancy
  • history of drug or alcohol abuse
  • treatment with corticosteroids
  • any other condition with poor prognosis
  • inability to provide Informed Consent.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Quadruple Blind

50 participants in 2 patient groups, including a placebo group

Atorvastatin
Active Comparator group
Treatment:
Drug: Atorvastatin
Placebo
Placebo Comparator group
Treatment:
Drug: Placebo

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems